The board of directors at Aligos Therapeutics has a history of experience with securities law, corporate finance, and tax from Harvard Law School as well as industry and competitive analysis and finance from Harvard Business School. They have also been involved with companies such as Neuron23 Inc., DiCE Molecules, and Adverum Biotechnologies, Inc. in the past.
View all